Clinical trial
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms…
NCT00174239 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00174239 |
|---|---|
| Title | Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease. |
| Official title | A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients. |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | cabergoline, controlled-release levodopa / carbidopa |
| Enrollment | 220 |
| Start date | Jul 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | May 25, 2007 |
| Countries | Australia, Italy, Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: